Table 1 Summary of efficacy - all treated patients (IMPACT-DCM)
From: The Aastrom experience
| Â | Â | IDCM | Â | Â | NIDCM |
|---|---|---|---|---|---|
| Â | Â | Ixmyelocel-T | Control | Ixmyelocel-T | Control |
Percent of patients with MACE adverse events | Â | Â | Â | Â | Â |
Enrolled patients | Â | 12 | 7 | 12 | 8 |
All MACE events (n (%)) | Â | 6 (50.0) | 5 (71.4) | 5 (41.7) | 2 (25.0) |
Total MACE events | Â | 8 | 8 | 8 | 3 |
Event on day 0/injection (n (%)) | Â | 2 (16.7) | 0 | 1 (8.3) | 0 |
Total MACE events day 0/injection | Â | 2 | 0 | 1 | 0 |
Event on days 1 to 365 (n (%)) | Â | 3 (25.0) | 4 (57.1) | 4 (33.3) | 1 (12.5) |
Total MACE events days 1 to 365 | Â | 5 | 7 | 7 | 1 |
Event on day 366+ (n (%)) | Â | 1 (8.3) | 1 (14.3) | 0 | 1 (12.5) |
Total MACE events day 366+ | Â | 1 | 1 | 0 | 2 |
Number of patients with improvements from baseline in efficacy/total patients in group | |||||
| Â | 12 months | 9/10 | 1/3 | 7/9 | 2/3 |
Increase in six minute walk test | 12 months | 6/10 | 0/3 | 8/9 | 3/3 |
Increase in echocardiogram ejection fraction | 12 months | 3/7 | 0/2 | 4/7 | 1/2 |